Shortages of breast cancer drug tamoxifen in Germany show the damaging knock-on effects of cost containment for the generics market, according to off-patent industry association Medicines for Europe, which says the case exemplifies an “urgent need to revise unsustainable pricing and tendering policies.”
The reports of tamoxifen shortages in Germany “raise legitimate concerns for patients and highlight the difficulties faced by off-patent medicines manufacturers operating in markets driven